TrialBMC medicine2023

Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial.

Zhe-Yu Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.